Lilly Fails Rehearing Bid, $177M Patent Verdict Stands

Lilly has lost its bid for a rehearing at the Federal Circuit, leaving intact a $177 million verdict against the company. The decision is significant because it involves patent claims that some experts believe could undermine medical innovation by allowing overly broad claims to survive.

A dissenting judge expressed concern that the ruling could have far-reaching implications, potentially allowing companies to circumvent the Supreme Court's Amgen decision. This decision sets a precedent for future cases involving pharmaceutical patents.